Toon Van Gorp highlighted our work on the ovaHRDscar biomarker at #ESGO2022 see full paper at biorxiv.org/content/10.110… Fernando Perez-Villatoro Medicine and Health, University of Helsinki

I am happy to share our recent work on an optimized HRD test for #ovarian cancer! Importantly, #ovaHRDscar is already implemented into the clinics HUS Helsingin yliopistollinen sairaala as basis for treatment with PARP inhibitors. Medicine and Health, University of Helsinki NSGO_org nature.com/articles/s4169…

Our work highlighted in the Finnish tabloid #iltalehti! Glad to see promotion of #ovariancancer awareness and information on PARP inhibitors to the public and #patients Suomen Syöpäpotilaat iCAN - Digital Precision Cancer Medicine

Excited to start #EASimmuneresponses With Alfredo Rodríguez,PhD Fernando Perez-Villatoro and Ashwini presenting our work!

Congrats Fernando Perez-Villatoro for great talk at the #rpuscienceday2023 #oncosys #ovariancancer #CancerResearch

I think we need to talk about how devastating this cancer microbiome refutation paper from Steven Salzberg 💙💛 and colleagues is. It really speaks to how devoid of critical thinking and intellectual depth our glam publishing ecosystem has become. 1/n biorxiv.org/content/10.110…

For this #FluorescenceFriday we bring a trhowback to one of our iconic serial killer T cells in honor of all the great work performed on understanding and enhancing T cell #immunotherapy using #LiveCellImaging for #CancerResearch

FarkkilaLab Lab highlighted in flash talks by Fernando Perez-Villatoro and Ada Junquera 💪🏼#AACRovc23

I'm really honored and thrilled to be awarded by The Cancer Society of Finland (Syöpäsäätiö) the dissertation/incentive grant. Thanks and thanks to my mentor Anniina Färkkilä.

Last night's #Färkkilab pikkujoulu was epic! 🎉 December vibes and a potluck with flavors from around the globe 🌍🍲. A lab that eats together, stays together! 👩‍🔬👨‍🔬

How do #cancer cells with resistant fates differ from the sensitive, already before the treatment? To answer this, we developed ReSisTrace, a cellular time-travel method that uses the similarity of sister cells to trace back pre-existing resistance. nature.com/articles/s4146…

Interested in spatial tumor immunology?Unique opportunity to join our Lab! Please share! jobs.helsinki.fi/job/Helsinki-P… farkkilab.org HiLIFE_Helsinki FIMM HelsinkiUni Medicine and Health, University of Helsinki iCAN - Digital Precision Cancer Medicine

How can we enhance the utility of models in clinics? This is an excellent article on the subject.

Looking forward to this EACR conference to get to know more interesting advances in the field. I'll be having a short talk presenting part of my PhD work. Eager to brainstorm and exchange ideas with the EACR community.

Really honored for the opportunity to present our work at the EACR-Cancer-Multiomics-and-Computational-Biology special conference. Thanks EACR, our collaborators and to my mentor Anniina Färkkilä

#TumorBoardTuesday Anniina Färkkilä Integrity CE, LLC 7/16 #TumorBoardTuesday 🔍Mini Tweetorial 4: Defining HRD tumors🔍 🧬Previous algorithms e.g. Telli2016 combined breast and ovarian samples, hindering precise HRD identification 🔍 #ovaHRDscar: game-changer in HRD detection and patient stratification nature.com/articles/s4169…

#TumorBoardTuesday Anniina Färkkilä Integrity CE, LLC 8/16 #TumorBoardTuesday 🔍Mini Tweetorial 5: #ovaHRDscar🔍 🔬By Fernando Perez-Villatoro FarkkilaLab & team: optimized criteria to identify HGSC HRD tumors beyond BRCAmut 📈#ovaHRDscar is now used for centralized testing of OvCan patients in 🇫🇮 to guide PARPi treatments HUS Helsingin yliopistollinen sairaala Medicine and Health, University of Helsinki

It's incredibly rewarding to be part of these research projects and contribute to improving clinical care for #OvCan patients. Read more about my #PhD projects 👇 🖥️#WorldOvarianCancerDay